Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

3.640 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion ↗

May 22, 2023

Both companies are working on treatments for gastrointestinal diseases.

Via Investor's Business Daily

Benzinga Pro's Top 5 Stocks To Watch For Monday, May 22, 2023: MU, RKT, DLTR, LDOS, IRWD ↗

May 22, 2023

Micron Technology (MU) - Shares were down about 4% Monday morning following a report the Chinese government found cybersecurity issues related to Micron's products. Chinese officials have asked

Via Benzinga

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

May 22, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference

May 09, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Recap: Ironwood Pharmaceuticals Q1 Earnings ↗

May 04, 2023

Via Benzinga

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023

May 08, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance

May 04, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

April 24, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Earnings Outlook For Ironwood Pharmaceuticals ↗

February 15, 2023

Via Benzinga

Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call

April 20, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences

February 27, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

February 16, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

February 13, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

3 No-Brainer Stocks to Buy Right Now for Less Than $25 ↗

February 04, 2023

All three healthcare stocks are showing solid long-term potential.

Via The Motley Fool

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call

February 02, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Why Ironwood Pharmaceuticals Shares Are Falling During Monday's Session ↗

January 09, 2023

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares are trading lower by 10.00% to $11.30 Monday afternoon after the company cut its FY22 sales guidance below analyst estimates and issued FY23 sales...

Via Benzinga

Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance

January 09, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals: Q3 Earnings Insights ↗

November 03, 2022

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

November 03, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call

October 20, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years ↗

September 06, 2022

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional...

Via Benzinga

Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients ↗

September 06, 2022

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.

Via Benzinga

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

September 06, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference

September 01, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Wells Fargo Maintains Equal-Weight Rating for Ironwood Pharmaceuticals: Here's What You Need To Know ↗

August 16, 2022

Wells Fargo has decided to maintain its Equal-Weight rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) and raise its price target from $12.00 to $13.00. Shares of Ironwood Pharmaceuticals are trading...

Via Benzinga

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

August 04, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call

July 21, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.